Merck & Co. stock advances as COPD trial opens new catalyst path - ad-hoc-news.de
Article excerpt
Highlighted: the sentence this signal was extracted from
Merck & Co. has started a new late-stage study for OHTUVAYRE as the drugmaker seeks to expand the clinical evidence around its COPD treatment. In a November 3 statement, Merck announced the initiation of ENHANCE-3, a Phase 3 randomized trial evaluating OHTUVAYRE, also known as ensifentrine, for the prevention of COPD exacerbations. Recruitment has begun, with the first participants enrolling in the United States. Merck said the study is designed for adults with COPD who have a history of moderate or severe exacerbations while receiving standard care. The company is positioning the trial as a step toward strengthening the evidence base for a medicine already approved in the United States for maintenance treatment of COPD. ENHANCE-3 is planned as a randomized, double-blind, placebo-controlled study involving approximately 2,136 patients in 28 countries. Participants will receive either OHTUVAYRE twice daily or placebo, with both groups continuing standard-of-care treatment. The primary endpoint is the annualized rate of adjudicated moderate or severe COPD exacerbations over 52 weeks. Secondary measures include lung function, health-related quality of life, severe exacerbations and overall safety. The design focuses on adults aged 40 to 80 with a confirmed COPD diagnosis, stable background therapy and at least one qualifying exacerbation during the previous year. OHTUVAYRE is a...
Keep reading with a free account
The rest of this article, and every signal for Merck, is in your free account.
